WASHINGTON--(BUSINESS WIRE)--March 22, 2006--BioSante Pharmaceuticals, Inc. (Amex:BPA) today will present new positive study results toward the development of a second-generation anthrax vaccine at the annual World Vaccine Congress here. BioSante is developing the anthrax vaccine for the U.S. Department of Defense under a subcontract with DynPort Vaccine Company.
